

Resource Summary Report

Generated by [dkNET](#) on Sep 21, 2026

Ultra-LEAF(TM) Purified anti-human CD28

RRID:AB_2616667

Type: Antibody

Proper Citation

BioLegend Cat# 302943, RRID:AB_2616667

Antibody Information

URL: http://antibodyregistry.org/AB_2616667

Proper Citation: BioLegend Cat# 302943, RRID:AB_2616667

Target Antigen: CD28

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC, IHC-F, Costim, FA

Antibody Name: Ultra-LEAF(TM) Purified anti-human CD28

Description: This monoclonal targets CD28

Target Organism: cynomolgus, rhesus, human

Clone ID: Clone CD28.2

Antibody ID: AB_2616667

Vendor: BioLegend

Catalog Number: 302943

Alternative Catalog Numbers: 302934, 302933, 302944, 302959, 302960

Record Creation Time: 20231110T034921+0000

Record Last Update: 20260831T204139+0000

Ratings and Alerts

No rating or validation information has been found for Ultra-LEAF(TM) Purified anti-human CD28.

No alerts have been found for Ultra-LEAF(TM) Purified anti-human CD28.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 15 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Carp DM, et al. (2026) Single-cell assessment of iron content in primary human T cells using laser ablation inductively coupled plasma mass spectrometry. *Cell reports methods*, 6(4), 101343.

Li YR, et al. (2025) Generating allogeneic CAR-NKT cells for off-the-shelf cancer immunotherapy with genetically engineered HSP cells and feeder-free differentiation culture. *Nature protocols*, 20(5), 1352.

Pedroza LA, et al. (2025) The Golgi complex governs natural killer cell lytic granule positioning to promote directionality in cytotoxicity. *Cell reports*, 44(1), 115156.

Zhang S, et al. (2025) Immunosequencing identifies signatures of T cell responses for early detection of nasopharyngeal carcinoma. *Cancer cell*, 43(8), 1423.

Kobiyama K, et al. (2025) Immunological analysis of LC16m8 vaccine: preclinical and early clinical insights into mpox. *EBioMedicine*, 115, 105703.

Poch T, et al. (2024) Intergenic risk variant rs56258221 skews the fate of naive CD4+ T cells via miR4464-BACH2 interplay in primary sclerosing cholangitis. *Cell reports. Medicine*, 5(7), 101620.

Lindner S, et al. (2024) Altered microbial bile acid metabolism exacerbates T cell-driven inflammation during graft-versus-host disease. *Nature microbiology*, 9(3), 614.

Berger S, et al. (2024) Preclinical proof of principle for orally delivered Th17 antagonist miniproteins. *Cell*, 187(16), 4305.

Lin CJ, et al. (2024) Genetic interactions reveal distinct biological and therapeutic implications in breast cancer. *Cancer cell*, 42(4), 701.

Wang Q, et al. (2024) The CARD8 inflammasome dictates HIV/SIV pathogenesis and disease progression. *Cell*, 187(5), 1223.

Yen M, et al. (2022) Facile discovery of surrogate cytokine agonists. *Cell*, 185(8), 1414.

Lötscher J, et al. (2022) Magnesium sensing via LFA-1 regulates CD8⁺ T cell effector function. *Cell*, 185(4), 585.

Glassman CR, et al. (2021) Structural basis for IL-12 and IL-23 receptor sharing reveals a gateway for shaping actions on T versus NK cells. *Cell*, 184(4), 983.

Sadik A, et al. (2020) IL4I1 Is a Metabolic Immune Checkpoint that Activates the AHR and Promotes Tumor Progression. *Cell*, 182(5), 1252.

Grandclaudon M, et al. (2019) A Quantitative Multivariate Model of Human Dendritic Cell-T Helper Cell Communication. *Cell*, 179(2), 432.